US equities
|
SPCX
$166.77
▲+4.91%
NVDA
$236.65
▲+1.15%
MU
$1,064.24
▼-0.99%
TSLA
$377.83
▲+1.95%
MSFT
$526.28
▲+1.69%
SNDK
$1,714.00
▼-0.35%
INTC
$116.94
▼-2.01%
META
$745.88
▲+2.44%
SPCX
$166.77
▲+4.91%
NVDA
$236.65
▲+1.15%
MU
$1,064.24
▼-0.99%
TSLA
$377.83
▲+1.95%
MSFT
$526.28
▲+1.69%
SNDK
$1,714.00
▼-0.35%
INTC
$116.94
▼-2.01%
META
$745.88
▲+2.44%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Heron Therapeutics, Inc.
Heron Therapeutics Announces Second Quarter 2026 Financial Results
August 10, 2026
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
July 27, 2026
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
U.S. District Court Issues Decision Regarding CINVANTI® Patents
June 02, 2026
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
May 11, 2026
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
April 27, 2026
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
February 26, 2026
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
February 17, 2026
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
January 09, 2026
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
December 04, 2025
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
November 04, 2025
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
October 29, 2025
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
From
Heron Therapeutics, Inc.
Via
GlobeNewswire
Tickers
HRTX
